Genetic Tests are performed once in a lifetime.
KIF6 Genotype – shows whether you are at risk for heart disease and if you are responsive to statins or combination therapy
SLCO1B1 Genotype – reveals risk for myopathy (muscle weakness, cramps, spasms, paralysis, inflammation, and stiffness) while taking certain statins
CYP2C19 Genotype – gives insight how the body processes Plavis. Poor or intermediate Metabolizers show that the individual will not receive the best results from the medication. Ultra-Rapid Metabolizers may increase one’s risk of a bleeding problem
LPA – Aspirin Genotype – carriers are at a higher risk for a heart attack, however, low-dose aspirin may reduce the risk. People who are non-carriers and take aspirin on a daily basis put themselves at a higher risk for a GI bleed.
4q25-AF Genotype – carriers have a higher risk for atrial fibrillation (AF) and stroke caused by AF.
LPA-Intron 25 Genotype – carriers are at a higher risk of heart disease.
9p21 Risk Genotype – carriers are at a higher risk of a heart attack before the age of 60 for women and age 50 for men, abdominal aortic aneurysm, or blocked coronary arteries.
APoE Genotype – There are 6 different types of ApoE genotypes 2/2, 2/3, 2/4, 3/3, 3/4 and 4/4. These different types reveal the body’s response to dietary fats. Those ;who are a 3/4 and a 4/4 have a higher risk for heart disease.
Guidelines for Assessment of Cardiovascular Risk in Asymptomatic Adults recommend targeting the following:
- Family History of premature CVD in first degree relatives.
- Individuals younger than 60 years with severe single risk abnormalities and are not candidate for pharmacotheraphy.
- Women younger than 60 with at least two CVD risk factors